Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
22.90
+0.16 (0.70%)
At close: Apr 8, 2026, 4:00 PM EDT
22.90
0.00 (0.00%)
After-hours: Apr 8, 2026, 4:10 PM EDT
Pelthos Therapeutics Employees
Pelthos Therapeutics had 92 employees as of December 31, 2025. The number of employees increased by 81 or 736.36% compared to the previous year.
Employees
92
Change (1Y)
81
Growth (1Y)
736.36%
Revenue / Employee
$182,554
Profits / Employee
-$470,859
Market Cap
76.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 92 | 81 | 736.36% | 92 | 0 |
| Dec 31, 2024 | 11 | 3 | 37.50% | 4 | 7 |
| Dec 31, 2023 | 8 | 6 | 300.00% | 4 | 4 |
| Sep 30, 2023 | 3 | 0 | - | 3 | 0 |
| Dec 31, 2022 | 2 | 0 | - | 2 | 0 |
| Sep 30, 2022 | 3 | 1 | 50.00% | 3 | 0 |
| Jun 30, 2022 | 3 | - | - | 3 | 0 |
| Dec 31, 2021 | 2 | - | - | 2 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Fortress Biotech | 101 |
| PolyPid | 75 |
| aTyr Pharma | 60 |
| Cognition Therapeutics | 28 |
| Gain Therapeutics | 25 |
| iBio, Inc. | 20 |
| MAIA Biotechnology | 13 |
PTHS News
- 8 days ago - Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain - GlobeNewsWire
- 20 days ago - Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 27 days ago - Pelthos Therapeutics to Present at 38th Annual ROTH Conference - GlobeNewsWire
- 2 months ago - Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics - Business Wire
- 3 months ago - Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance - GlobeNewsWire
- 3 months ago - Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - GlobeNewsWire
- 5 months ago - Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 5 months ago - Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - GlobeNewsWire